首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Leukemia & Lymphoma

Leukemia & Lymphoma杂志,由Informa Healthcare出版,于1989年创刊,Monthly,出版语言English,ISSN:1042-8194,E-ISSN:1029-2403。

投稿咨询
Leukemia & Lymphoma
Leukemia & Lymphoma
Leukemia & Lymphoma
SCI SCIE

杂志介绍

JCR分区
Q3
中科院分区
4区
影响因子
2.1
CiteScore
3.9
期刊收录
SCI、SCIE

Leukemia & Lymphoma(中文译名:《白血病和淋巴瘤》),ISSN:1042-8194,EISSN:1029-2403,是Informa Healthcare出版的国际性学术期刊,创刊于1989年,以Monthly形式稳定发行,2026年总发文量约214篇。该刊采用非OA开放访问,学科归属为医学 - 血液学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.1,2025年期刊CiteScore为3.9,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Leukemia & Lymphoma长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约1.8月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Italy、GERMANY (FED REP GER)、France、England、Australia等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMMAYO CLINIC、CORNELL UNIVERSITY、MEMORIAL SLOAN KETTERING CANCER CENTER、HARVARD UNIVERSITY、ASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP)、DANA-FARBER CANCER INSTITUTE等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学 HEMATOLOGY 血液学
4区 4区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
4区 4区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
4区 4区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q3 61 / 103

41.3

学科:ONCOLOGY SCIE Q3 236 / 333

29.3

学科:HEMATOLOGY SCIE Q3 67 / 103

35.44

学科:ONCOLOGY SCIE Q3 249 / 333

25.38

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q3 51 / 99

49

学科:ONCOLOGY SCIE Q3 217 / 328

34

学科:HEMATOLOGY SCIE Q3 66 / 100

34.5

学科:ONCOLOGY SCIE Q3 240 / 328

26.98


中国学者近期发文

1
Single-cell technologies in deciphering drug resistance of multiple myeloma: mechanistic insights and clinical translation prospect

Author:Wu, Jun; Dong, Haibo; Xu, Xuejing; Wang, Mei

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2649879

2
Umbilical cord-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a real-world stud

Author:Niu, Yanyan; Chen, Bin; Zhao, Yaqian; Yu, Xinru; Wang, Tao; Ma, Liangming

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2634172

3
MBP1 inhibits AML proliferation through downregulating noncanonical Wnt/Ca2+ signaling pathwa

Author:Gao, Beibei; Yan, Wenli; Xue, Jingjing; Zhang, Shanshan; Wang, Furong; Kang, Zhijie; Ren, Jinhong; Yan, Jinsong; Wang, Haina

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2661083

4
A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphom

Author:Hu, Lina; Lu, Bo; Wei, Xiaolei; Wang, Ying; Xie, Mian; Li, Jun; Feng, Chun; Li, Guoqiang; Qiu, Xiao; Zhang, Jiahe; Guo, Xutao; Zhong, Zhiren; Li, Xiaoqing; Zhang, Qian; Zhou, Jihao

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2654977

5
Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicit

Author:Tian, Ji-xin; Liao, Ying-xi; Wang, Xiao-xu; Wang, Xiao-dan; Li, Shan; Liu, Dong-xue; Sun, Xin-yuan; Zhang, Ping; Miao, Wen-juan

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2634179

6
Combined oral PI3Kδ inhibitor linperlisib and HDAC inhibitor chidamide in relapsed/refractory peripheral T-cell lymphoma: a multicenter phase 1 tria

Author:Wei, Chong; Su, Liping; Liu, Lihong; Zhou, Daobin; Zhang, Wei

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2631800

7
Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysi

Author:Hao, Xiaoyu; Zhang, Jiabin; Liu, Shuozi; Luo, Lan; Li, Chunyuan; Zhang, Weilong; Wang, Jing; Yang, Ping; Jing, Hongmei

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2637864

8
Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinio

Author:Kim, Won Seog; Al Mansour, Mubarak; Cheah, Chan; Farias, Joao Samuel De Holanda; Elghandour, Ashraf; Hawkes, Eliza; Huang, Haiwen; Ko, Bor Sheng; De Farias, Danielle Leao Cordeiro; Li, Zhiming; Ong, Shin Yeu; Pavlovsky, Miguel Arturo; Zincer, Fernando Perez; Song, Yuqin

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2640453

9
Reduced-dose anti-thymocyte globulin combined with post-transplant cyclophosphamide versus standard ATG for graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplantation: a focus on chronic GVHD reductio

Author:Guo, Wenyi; Li, Bo; Tang, Li; Peng, Liang; Guo, Shuli

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2645932

10
Coexistence of BCR::ABL1 with IKZF1::ETV6 fusion in an adult patient with acute B-lymphoblastic leukemi

Author:Tan, Kai-Wen; Xu, Yi; Huang, Yuan-Hong; Qiu, Qiao-Cheng; Lyu, Xiao-Yu; Huang, Si-Man; Wang, Zi-Hao; Li, Hui-Ying; Xu, Shun-Zhe; Liu, Fang-Tong; Liu, Shen-Hao; Zhang, Yang; Xue, Sheng-Li; Dai, Hai-Ping

Journal: LEUKEMIA & LYMPHOMA. 2026; Vol. , Issue , pp. -. DOI: 10.1080/10428194.2026.2621828


在线咨询

Leukemia & Lymphoma

国际简称:LEUKEMIA LYMPHOMA参考译名:白血病和淋巴瘤

年发文量:214 CiteScore:3.9 是否预警:否 Gold OA文章占比:12.17% 研究类文章占比:72.90%

杂志社联系方式:TAYLOR & FRANCIS LTD, 4 PARK SQUARE, MILTON PARK, ABINGDON, ENGLAND, OXON, OX14 4RN

Leukemia & Lymphoma